Evidence map›Paper›PMID 40108919›Full record

ArticleCurrent drug metabolism2025

Effect of

Weiyue Zhang, Ruidong Wang, Lin Li, Jiani Chen, Jingwen Zhai, Wei Wang, Shiyi Liu, Hong Liu, Hua Wei, Shu Han

Abstract read
PubMed Publisher
In one paragraph

Article in Current drug metabolism, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Weiyue ZhangSchool of Nursing, Beijing University of Chinese Medicine, Beijing, 100029, China.
Ruidong WangDepartment of Good Clinical Practice, Clinical Research Institute, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, 200438, China.
Lin LiDepartment of Nephrology, Second Affiliated Hospital of Naval Medical University, Shanghai, 200003, China.
Jiani ChenDepartment of Good Clinical Practice, Medical Guarantee Center, Second Affiliated Hospital of Naval Medical University, Shanghai, 200003, China.
Jingwen ZhaiDepartment of Good Clinical Practice, Medical Guarantee Center, Second Affiliated Hospital of Naval Medical University, Shanghai, 200003, China.
Wei WangDepartment of Good Clinical Practice, Medical Guarantee Center, Second Affiliated Hospital of Naval Medical University, Shanghai, 200003, China.
Shiyi LiuDepartment of Good Clinical Practice, Medical Guarantee Center, Second Affiliated Hospital of Naval Medical University, Shanghai, 200003, China.
Hong LiuInformation Center, Second Affiliated Hospital of Naval Medical University, Shanghai, 200003, China.
Hua WeiDepartment of Good Clinical Practice, Medical Guarantee Center, Second Affiliated Hospital of Naval Medical University, Shanghai, 200003, China.
Shu HanInstitute of Organ Transplantation, Second Affiliated Hospital of Naval Medical University, Shanghai, 200003, China.

Funding

National Natural Science Foundation of China 81303113project of Industry- University-Research Cooperation 13DZ1930600
6 · The paper itself

Abstract

backgroundPrevious studies have shown that WZC can increase tacrolimus blood concentration when co-administered. However, limited knowledge exists regarding the pharmacokinetics of both tacrolimus and the bioactive lignans in WZC when administered simultaneously in renal transplantation patients.

aimsThis study aimed to investigate the pharmacokinetics of tacrolimus and multiple bioactive lignans in Wuzhi capsule (WZC) when co-administered with 5 bioactive components in renal transplantation recipients.

objectivesThe objective of this study was to develop a method for simultaneous quantification of tacrolimus and multiple bioactive lignans in WZC using liquid-liquid extraction followed by LC-MS/MS analysis.

methodsA liquid-liquid extraction method combined with LC-MS/MS analysis was developed for simultaneous quantification of tacrolimus and multiple bioactive lignans in WZC. Human whole blood samples were analyzed, and the accuracy and precision of the method were evaluated.

resultsThe developed method showed good linearity and accuracy for the quantification of tacrolimus and bioactive lignans in WZC. Pharmacokinetic analysis revealed significant effects of WZC co-administration on both V/F and CL/F in renal transplantation patients.

conclusionThis study demonstrated that simultaneous administration of WZC had notable effects on the pharmacokinetics of tacrolimus and bioactive lignans in renal transplantation patients. The developed method proved to be reliable and sensitive for determining the whole blood concentrations of tacrolimus and WZC, making it suitable for pharmacokinetic studies in transplant patients.

Indexed as

Drugs, Chinese HerbalImmunosuppressive AgentsKidney TransplantationTacrolimusAdultCapsulesChromatography, LiquidFemaleHumansLignansLiquid-Liquid ExtractionMaleMiddle AgedTandem Mass SpectrometryCapsulesDrugs, Chinese HerbalImmunosuppressive AgentsLignansTacrolimuswuzhiconcentration.LC-MS/MSpharmacokineticsrenal transplantationtacrolimusWuzhi capsule

Identifiers

PMID40108919

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.